Statistical power of clinical trials increased while effect size remained stable: An empirical analysis of 136,212 clinical trials between 1975 and 2014 by Lamberink, Herm J. et al.
Bond University
Research Repository
Statistical power of clinical trials increased while effect size remained stable
Lamberink, Herm J.; Otte, Willem M.; Sinke, Michel R.T.; Lakens, Daniël; Glasziou, Paul P.;
Tijdink, Joeri K.; Vinkers, Christiaan H.
Published in:
Journal of Clinical Epidemiology
DOI:
10.1016/j.jclinepi.2018.06.014
Published: 01/10/2018
Document Version:
Peer reviewed version
Link to publication in Bond University research repository.
Recommended citation(APA):
Lamberink, H. J., Otte, W. M., Sinke, M. R. T., Lakens, D., Glasziou, P. P., Tijdink, J. K., & Vinkers, C. H. (2018).
Statistical power of clinical trials increased while effect size remained stable: An empirical analysis of 136,212
clinical trials between 1975 and 2014. Journal of Clinical Epidemiology, 102, 123-128.
https://doi.org/10.1016/j.jclinepi.2018.06.014
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
1 
 
This is the author version of an article published in J Clin Epidemiol. 2018 Oct;102:123-128. 1 
doi: 10.1016/j.jclinepi.2018.06.014. 2 
Title: Statistical power of clinical trials has increased while effect size remained stable: an 3 
empirical analysis of 136,212 clinical trials between 1975-2014 4 
Authors 5 
Herm J Lamberink 
a#
, Willem M Otte 
a,b#
*, Michel RT Sinke 
b
, Daniël Lakens 
c
, Paul P Glasziou 6 
d
, Joeri K Tijdink 
e
, and Christiaan H Vinkers 
f 
7 
#
Authors contributed equally 8 
Affiliations
 9 
a 
Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center 10 
Utrecht and Utrecht University, P.O. Box 85090, 3508 AB, Utrecht, The Netherlands
 11 
b 
Biomedical MR Imaging and Spectroscopy group, Center for Image Sciences, University 12 
Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht , The 13 
Netherlands
 14 
c 
School of Innovation Sciences, Eindhoven University of Technology, Den Dolech 1, 5600 MB 15 
Eindhoven, The Netherlands
 16 
d
 Centre for Research in Evidence-Based Practice, Faculty of Health Sciences and Medicine, 17 
Bond University, Gold Coast, Queensland, Australia
 18 
e 
Department of Philosophy, VU University, De Boelelaan 1105, 1081 HV Amsterdam, The 19 
Netherlands
 20 
2 
 
f 
Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht and 21 
Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands 22 
 23 
Corresponding author 24 
Herm J Lamberink, Department of Child Neurology, Brain Center Rudolf Magnus, University 25 
Medical Center Utrecht and Utrecht University, Room KC 03.063.0, P.O. Box 85090, 3508 AB, 26 
Utrecht, The Netherlands. E: h.j.lamberink@umcutrecht.nl, T: +31 88 755 6030. 27 
https://orcid.org/0000-0003-1379-3487 28 
3 
 
Abstract 29 
Objective. To study the statistical power of randomized clinical trials and examine 30 
developments over time. 31 
Study Design and Setting. We analysed the statistical power in 136,212 clinical trials between 32 
1975 and 2014 extracted from meta-analyses from the Cochrane database of systematic reviews. 33 
We determined study power to detect standardized effect sizes, where power was based on the 34 
meta-analysed effect size. Average power, effect size and temporal patterns were examined for 35 
all meta-analyses and a subset of significant meta-analyses.  36 
Results. The number of trials with power ≥80% was low (7%) but increased over time: from 5% 37 
in 1975–1979 to 9% in 2010–2014. In significant meta-analyses, the proportion of trials with 38 
sufficient power increased from 9% to 15% in these years (median power increased from 16%  to 39 
23%). This increase was mainly due to increasing sample sizes, whilst effect sizes remained 40 
stable with a median Cohen’s h of 0.09 (IQR 0.04-0.22) and a median Cohen’s d of 0.20 (0.11-41 
0.40).  42 
Conclusion. This study demonstrates that sufficient power in clinical trials is still problematic, 43 
although the situation is slowly improving. Our data encourage further efforts to increase 44 
statistical power in clinical trials to guarantee rigorous and reproducible evidence-based 45 
medicine. 46 
Key words: statistical power; clinical trial; randomized  47 
Running title: Statistical power in clinical trials over time 48 
Word count: 198 (abstract), 2125 (body) 49 
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What is new? 50 
 Study power in clinical trials is low: 7% of trials were sufficiently powered (≥0.8) and 51 
14% had a power above 0.5; within significant meta-analyses 12% was sufficiently 52 
powered and 24% had a power above 0.5.  53 
 Study power has increased from 5% in 1975–1979 to 9% in 2010–2014. 54 
 Average effect sizes are small and did not increase over time. 55 
 When determining the required sample size of a clinical trial, small effects should be 56 
assumed to ensure an adequate sample size. 57 
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1. Introduction 58 
The practice of conducting scientific studies with low statistical power has been consistently 59 
criticized across academic disciplines 
1–5
. Statistical power is the probability that a study will 60 
detect an effect when there is a true effect to be detected. Underpowered studies have a low 61 
chance of detecting true effects and have been related to systematic biases including inflated 62 
effect sizes and low reproducibility 
6,7
. Low statistical power has been demonstrated, amongst 63 
others, in the fields of neuroscience, economics and psychology 
4,8–10
. For clinical trials in the 64 
field of medicine, the issue of sample size evaluation and statistical power is essential since 65 
clinical decision making and future research are based on these clinical trials 
11,12
. Moreover, low 66 
power in clinical trials may be unethical in light of the low informational value from the outset 67 
while exposing participants to interventions with possible negative (side) effects 
1
. Also in 68 
medical research statistical power is low 
3,8
, but a systematic overview of temporal patterns of 69 
power, sample sizes, and effect sizes across medical fields does not exist. In the current study, 70 
we provide a comprehensive overview of study power, sample size, and effect size estimates of 71 
clinical trials published since 1975 which are included in the Cochrane database of systematic 72 
reviews, and analyse emerging trends over time.  73 
6 
 
2. Materials and Methods 74 
Data were extracted and calculated from trials included in published reviews from the second 75 
Issue of the 2017 Cochrane database of systematic reviews. Cochrane reviews only include meta-76 
analyses if the methodology and outcomes of the included trials are comparable across study 77 
populations. Meta-analysis data is available for download in standardized XML-format for those 78 
with an institutional Cochrane Library license. We provide open-source software to convert these 79 
data and reproduce our entire processing pipeline 
13
. 80 
Trials were selected if they were published after 1974 and if they were included in a meta-81 
analysis based on at least five trials. Since relatively few studies from 2015-2017 were included 82 
in our meta-analyses, these years were excluded. For each individual clinical trial, publication 83 
year, outcome estimates (odds or risk ratio, risk difference or standardized mean difference) and 84 
group sizes were extracted. For the main analyses all meta-analyses were used; sub-analyses 85 
were performed on only the meta-analyses with a reported p-value below 0.05, irrespective of the 86 
p-value of the individual trial. For meta-analyses reporting standardized mean differences 87 
(Cohen’s d), the reported meta-analytic effect size was used to compute individual study power. 88 
For meta-analyses reporting dichotomous outcomes, meta-analytic effect size (Cohen’s h) was 89 
computed using arcsine transformation of proportions 
12
. The main analysis used the effect size 90 
extracted from the meta-analysis, which was performed as either fixed-, or random-effects as 91 
judged by the authors of that specific Cochrane review. As a sensitivity analysis we recomputed 92 
the meta-analytic effect size using fixed effects, random effects, and unrestricted weighted least 93 
squares/ weighed average of the adequately powered (WLS-WAAP) 
14
. This latter method was 94 
developed to optimize results from meta-analysis in the context of selective reporting bias: WLS-95 
WAAP performs better than both fixed and random effects analyses in the context of publication 96 
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bias, allows to correct for heterogeneity, and gives similar results to fixed effects when both are 97 
not present 
14,15
. Study power was computed in R using the ‘pwr’ package 16. Following 98 
minimum recommendations for the statistical power of studies 
12
, comparisons with a power 99 
above or equal to 80% were considered to be sufficiently powered. Study power, group sizes and 100 
effect sizes over time were summarised and visualized for all clinical trials. 101 
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3. Results  102 
Data from 136,212 clinical trials were available, from 11,852 meta-analyses in 1,918 Cochrane 103 
reviews. Of these, 77,947 trials (57.2%) were from a meta-analysis with an overall p-value below 104 
0.05, from 5,903 meta-analyses (49.8%) in 1,411 Cochrane reviews (73.6%). In the original 105 
systematic reviews fixed effects were used in 55% of meta-analyses whereas 45% used random 106 
effects. Of all trials 7.3% had a statistical power of at least 80% (the recommended minimum 
12
, 107 
which we shall denote as ‘sufficient power’) to detect an effect size as large as the meta-analysed 108 
effect size; for the subset of significant meta-analyses this was 12.4%. The median power 109 
(interquartile range, IQR) was 9% (95% confidence interval (CI) 6-26%), which was 20% (10-110 
48%) for significant meta-analysis (Table 1).  111 
Table 1 | Proportion studies with sufficient power and median power. 
Selected meta-analyses 
N meta-analyses  
(N studies) 
Sufficient (≥0.8) 
power (95% CI) 
Median power 
(IQR) 
All 11,852 (136,212) 7.3 (7.2-7.5) 0.09 (0.06-0.26) 
Significant  5,903 (77,947) 12.4 (12.2-12.7) 0.20 (0.10-0.48) 
CI: confidence interval. FE: fixed effects. IQR: interquartile range. 
 112 
Between 1975–1979 and 2010–2014 the proportion of sufficiently powered studies rose from 113 
5.1% (4.3-6.1) to 8.5% (8.0-8.9) (Figure 1, top right) while the median power changed from 0.09 114 
(IQR 0.06-0.26) to 0.10 (IQR 0.06-0.30) (Figure 1, left). Within significant meta-analyses the 115 
rise was more clear: study power increased with the median rising from 16% (IQR 10-39) to 116 
23% (IQR 12-55) (Supplementary Figure 1, left), and the proportion of sufficiently powered 117 
studies from 9.0% (7.6-10.6) to 14.7% (13.9 - 15.5) (Supplementary Figure 1, top right). This 118 
trend is seen across medical disciplines (Supplementary Figure 2). When the threshold for 119 
sufficient power is set at a minimum of 50% power, the proportion of trials with sufficient power 120 
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is still low but also rising (Supplementary Figure 3). The distribution of power showed a bimodal 121 
pattern, with many low-powered studies and a small peak of studies with power approaching 122 
100% (Figure 1 and Supplementary Figure 1, bottom right).  123 
 124 
 125 
Figure 1 | Statistical power of clinical trials between 1975 and 2014 (left). Individual 126 
comparisons are shown as semi-transparent dots. Median power is shown in red with 127 
interquartile range as error bars. The percentage of adequately powered trial comparisons 128 
(i.e. ≥80% power) is increasing over time (top right). The biphasic power distribution of 129 
the trials in general is apparent (bottom right). 130 
 131 
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The average number of participants enrolled in a trial arm increased over time (Figure 2, top 132 
left). The median group size in 1975–1979 ranged between 30 and 45; for the years 2010–2014 133 
the median group size was between 74 and 92. The median effect sizes are summarized in Table 134 
2; these remained stable over time (Figure 2). The standardized effect sizes were small, with a 135 
median Cohen’s h of 0.09 (0.04-0.22) and a median Cohen’s d of 0.20 (0.11-0.40) (Table 2); 136 
Figure 3 shows the distribution plots for these two measures; for the significant meta-analyses 137 
the median effect sizes were higher (Supplementary Table 1 and Supplementary Figure 4). 138 
Sensitivity analyses showed robust results regardless of the method for performing meta-139 
analysis. The proportion of studies with sufficient power was between 7.2% and 7.5% depending 140 
on the method; the median power remained 9% across methods (Supplementary Table 2). 141 
 142 
 143 
 144 
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Figure 2 | The number of participants (N) enrolled in each trial arm, between 1975 and 2014 in 145 
red semi-transparent dots (top left). Corresponding effect sizes – classified in Cochrane 146 
reviews as risk difference, standardized mean difference, (Peto) odds ratio or risk ratio – 147 
are shown in the remaining plots. Median and interquartile data are plotted annually. 148 
Years with less than ten studies with the specific measure were omitted from the plot. 149 
 150 
 151 
Figure 3 | Distribution plot of standardized effect sizes, based on the meta-analytic effect size 152 
from all meta-analyses. Cohen’s h was based on the proportion of events in the meta-153 
analysis in case of dichotomous study outcomes. In studies comparing means the 154 
standardized mean difference (Cohen’s d) of the meta-analysis was directly available in 155 
the Cochrane database.  156 
 157 
 158 
Table 2 | Median effect sizes for all meta-analyses  
Reported effect measure 
N meta-analyses (n 
included trials) 
Raw effect size: median 
(IQR) Standard effect size* 
Odds ratio  1,798 (17,772) 1.37 (1.15-1.93) 
} 0.09 (0.04-0.22) Peto odds ratio  783 (8,421) 1.31 (1.11-1.79) Risk ratio  8,459 (100,534) 1.26 (1.09-1.64) 
Risk difference  187 (2,275) 0.02 (0.00-0.06) 
Standardized mean difference  625 (7,210) 0.20 (0.11-0.40) 0.20 (0.11-0.40) 
12 
 
Median effect sizes are computed based on the meta-analysis; every meta-analysis is taken into account 
once irrespective of the number of included trials. To obtain a meaningful summary statistic, effect sizes 
were transformed to be unidirectional: the absolute number of risk differences and standardized mean 
differences was taken, and for (Peto) odds ratios and risk ratio’s effects below one were inversed (1 
divided by the effect, e.g. an RR of 0.5 becomes 2.0). These transformations only change the direction 
and not the magnitude of the effect.  
N = number of meta-analyses (number of included studies) 
*standard effect size: Cohen’s d or h 
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4. Discussion 159 
The current study provides an overview of the statistical power in 136,212 clinical trials across 160 
all medical fields. Our analyses demonstrate that effect sizes are small-, and that sample sizes of 161 
most clinical trials are too small to detect such an effect. Only 7% of individual trials had 162 
sufficient power to detect the observed effect from its respective meta-analysis. Though there is 163 
considerable room for improvement, an encouraging trend is the number of trials with sufficient 164 
power has increased over four decades from 5% to 9%, and from 9% to 15% in trials from 165 
significant meta-analyses. On average, sample sizes have doubled between 1975 and 2014 166 
whereas effect sizes did not increase over time.  167 
The distribution of effect sizes (with a median Cohen’s h of 0.09 and a median Cohen’s d of 168 
0.20, respectively) shows that large effects are rare. This information should be taken into 169 
account when designing a clinical trial and determining the required minimum sample size. The 170 
effect size summary statistics provided here could also be used as standard prior in Bayesian 171 
modelling in medical research, since they are based on many thousands of trials covering the 172 
general medical field.  173 
Our results are in agreement with a study by Turner and colleagues in which they also used the 174 
Cochrane database of systematic reviews (2008 version) to describe study power in clinical trials 175 
3
. This study also showed low study power with a bimodal pattern of many low-powered studies 176 
and a small proportion of well-powered studies. The Turner study demonstrated a median power 177 
of 8%, whereas we find a comparable median power of 9% across all meta-analyses. This 178 
slightly higher percentage could be explained by the inclusion of more recent high-powered 179 
studies, or the exclusion of meta-analyses with less than five trials.   180 
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Our use of meta-analytic effect sizes to compute study power has two important shortcomings. 181 
First, although it is a fair –and the only available– approximation of the true effect of a given 182 
therapy, power and sample size calculations are designed to be performed a-priori. We would 183 
fully endorse that for an individual study there is no space for a post-hoc power computation. 184 
Second, it may be questioned whether statistical power can be computed when the estimation of 185 
the effect size includes a null-effect in the 95% confidence interval. If there is no effect, a power 186 
calculation cannot be performed. If the null-hypothesis: “there is no effect” cannot be rejected, 187 
there is no clear effect size estimation available as the basis for the power calculation. We have 188 
therefore also included all results for the subset of significant meta-analyses.  189 
By analysing the temporal pattern across four decades, we identified an increase of study power 190 
over time. Moreover, since effect size estimates remained stable across time, our study clearly 191 
shows the need to increase sample sizes to design well-powered studies. A study on sample sizes 192 
determined in preregistration on ClinicalTrials.gov between 2007-2010 showed that over half of 193 
the registered studies included a required sample of 100 participants or less in their protocol 
17
. 194 
We found that, within the published trials that have been included in a Cochrane meta-analysis, 195 
the findings are in line with these results, and although the average sample size has doubled since 196 
the 1970’s, and median sample size in 2010–2014 was between 150-180.  197 
An argument in defence of performing small (or underpowered) studies has been made based on 198 
the idea that small studies can be combined in a meta-analysis to increase power. Halpern and 199 
colleagues already explained the invalidity of this argument in 2002 
1
, most importantly because 200 
small studies are more likely to produce results with wide confidence intervals and large p-201 
values, and thus are more likely to remain unpublished. An additional risk of conducting 202 
uninformative studies is that a lack of an effect due to low power might decrease the interest by 203 
15 
 
other research teams to examine the same effect. A third argument against performing small 204 
studies is given in a study by Nuijten and colleagues 
7
, which indicates that the addition of a 205 
small, underpowered study to a meta-analysis may actually increase the bias of an effect size 206 
instead of decreasing it.  207 
There are several limitations to consider in the interpretation of our results. First, the outcome 208 
parameter studied in the meta-analysis may be different than the primary outcome of the original 209 
study; it may have been adequately powered for a different outcome parameter. This could result 210 
in lower estimates of average power, although it seems unlikely that the average effect size of the 211 
primary outcomes is higher than the effect sizes in the Cochrane database. Second, in contrast, 212 
effect sizes from meta-analyses are considered to be an overestimation of the true effect because 213 
of publication bias 
7,18. Lastly, in determining the required power for a study a ‘one size fits all’ 214 
principle does not necessarily apply as Schulz & Grimes 
19
 also argue. However, although 215 
conventions are always arbitrary 
12
 a cut-off for sufficient power at 80% is reasonable. 216 
With statistical power consistently increasing over time, our data offer perspective and show that 217 
we, the scientific community, are heading in the right direction. Nevertheless, it is clear that most 218 
clinical trials remain underpowered. Although there may be exceptions justifying small clinical 219 
trials, we believe that in most cases underpowered studies are problematic. Clinical trials 220 
constitute the backbone of evidence-based medicine, and individual trials would ideally be 221 
interpretable in isolation, without waiting for a future meta-analysis. To further improve the 222 
current situation, trial pre-registrations could include a mandatory section justifying the sample 223 
size, based on realistic expectations of the effect size, and preferably with explicit reference to 224 
earlier published results in the same field. If no prior literature exists for the specific condition or 225 
treatment, we recommend that small effects should be assumed. Large-scale collaborations with 226 
16 
 
the aim of performing either a multi-centre study or a prospective meta-analysis may also 227 
increase sample sizes when individual teams lack the resources to collect larger sample sizes. 228 
Another important way to introduce long-lasting change is by improving the statistical education 229 
of current and future scientists 
5
.  Even though our analyses demonstrate that sufficient power in 230 
clinical trials is still problematic, the situation seems to be slowly improving. Together, these 231 
results encourage further efforts to increase statistical power in clinical trials to guarantee 232 
rigorous and reproducible evidence-based medicine. 233 
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Figure legends 287 
All figures should be printed in colour. 288 
 289 
 290 
Figure 1 | Statistical power of clinical trials between 1975 and 2014 (left). Individual 291 
comparisons are shown as semi-transparent dots. Median power is shown in red with 292 
interquartile range as error bars. The percentage of adequately powered trial comparisons 293 
(i.e. ≥80% power) is increasing over time (top right). The biphasic power distribution of 294 
the trials in general is apparent (bottom right). 295 
 296 
 297 
Figure 2 | The number of participants (N) enrolled in each trial arm, between 1975 and 2014 in 298 
red semi-transparent dots (top left). Corresponding effect sizes – classified in Cochrane 299 
reviews as risk difference, standardized mean difference, (Peto) odds ratio or risk ratio – 300 
are shown in the remaining plots. Median and interquartile data are plotted annually. 301 
Years with less than ten studies with the specific measure were omitted from the plot. 302 
 303 
 304 
 Figure 3 | Distribution plot of standardized effect sizes. Cohen’s h was based on the proportion 305 
of events in the meta-analysis in case of dichotomous study outcomes. In studies 306 
comparing means the standardized mean difference (Cohen’s d) of the meta-analysis was 307 
directly available in the Cochrane database.  308 
 309 
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SUPPLEMENTARY MATERIALS 310 
 311 
Supplementary Figure 1 | Statistical power of clinical trials between 1975 and 2014 from meta-312 
analyses with p-value <0.05 (left). Individual comparisons are shown as semi-transparent 313 
dots. Median power is shown in red with interquartile range as error bars. The percentage 314 
of adequately powered trial comparisons (i.e. ≥80% power) is increasing over time (top 315 
right). The biphasic power distribution of the trials in general is apparent (bottom right). 316 
21 
 
317 
Supplementary Figure 2 | Statistical power of clinical trials between 1975 and 2014 318 
across twelve major medical disciplines (disciplines with >4000 comparisons were 319 
included). Individual trial comparisons are visualized using red semi-transparent dots. 320 
Median and interquartile data is plotted and centred at five-year intervals. The percentage 321 
of adequately powered studies (≥80% power, indicated with dotted lines) over the entire 322 
period is plotted between parentheses following the disciplines’ names. 323 
 324 
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 A 325 
 B 326 
Supplementary Figure 3 | Comparison of the percentage of trial comparisons with a minimum 327 
power of 0.5 and 0.8 over time. A = using all meta-analyses. B = using only significant 328 
meta-analyses.  329 
330 
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 331 
Supplementary Table 1 | Median effect sizes for all meta-analyses with p-value <0.05 
Reported effect measure 
N meta-analyses (n 
included trials) 
Raw effect size: median 
(IQR) Standard effect size* 
Odds ratio  879 (10,234) 1.83 (1.41-2.63) 
} 0.21 (0.12-0.36) Peto odds ratio  348 (3,956) 1.83 (1.43-2.92) Risk ratio  4230 (57,633) 1.57 (1.30-2.22) 
Risk difference  68 (981) 0.08 (0.04-0.14) 
Standardized mean difference  378 (5,143) 0.31 (0.19-0.51) 0.31 (0.19-0.51) 
Median effect sizes are computed based on the meta-analysis; every meta-analysis is taken into account 
once irrespective of the number of included trials. To obtain a meaningful summary statistic, effect sizes 
were transformed to be unidirectional: the absolute number of risk differences and standardized mean 
differences was taken, and for (Peto) odds ratios and risk ratio’s effects below one were inversed (1 
divided by the effect, e.g. an RR of 0.5 becomes 2.0). These transformations only change the direction 
and not the magnitude of the effect.  
N = number of meta-analyses (number of included studies) 
*standard effect size: Cohen’s d or h 
332 
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 333 
 334 
Supplementary Figure 4 | Distribution plot of standardized effect sizes, based on the meta-335 
analytic effect size from all significant meta-analyses. Cohen’s h was based on the proportion of 336 
events in the meta-analysis in case of dichotomous study outcomes. In studies comparing means 337 
the standardized mean difference (Cohen’s d) of the meta-analysis was directly available in the 338 
Cochrane database.339 
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 340 
Supplementary Table 2 | Proportion studies with sufficient power and median power, through different 
methods of meta-analysis. 
Selected meta-
analyses Method  
N meta-analyses  
(N studies) 
Sufficient (≥0.8) 
power (95% CI) Median power (IQR) 
All Original 11,852 (136,212) 7.3 (7.2-7.5) 0.09 (0.06-0.26) 
All FE 11,852 (136,212) 7.2 (7.1-7.4) 0.09 (0.06-0.26) 
All RE 11,852 (136,212) 7.5 (7.4-7.6) 0.09 (0.06-0.26) 
All WLS-WAAP 11,852 (136,212) 7.2 (7.1-7.3) 0.09 (0.06-0.26) 
Significant  Original 5,903 (77,947) 12.4 (12.2-12.7) 0.20 (0.10-0.48) 
Significant FE 5,409 (73,533) 12.9 (12.7-13.2) 0.20 (0.09-0.49) 
Significant RE 4,622 (65,156) 14.2 (13.9-14.5) 0.22 (0.10-0.54) 
Significant WLS-WAAP 5,266 (70,720) 12.4 (12.1-12.6) 0.18 (0.09-0.47) 
CI: confidence interval. FE: fixed effects. IQR: interquartile range. Original: fixed- or random effects as 
performed in original meta-analysis. RE: random effects. WLS-WAAP: weighted least squares / weighted 
average of the adequately powered. 
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